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also positive for desmin and h-caldesmon, suggesting that a fraction 
of these cells have a smooth muscle-like phenotype. In mixed adeno-
carcinoma with a BAC component, subepithelial myoﬁbroblasts were 
present in the BAC componenet, but there seemed to be a gradual loss 
of a typical subepithelial pattern of myoﬁbroblasts in invasive areas; 
they either disappeared partially or formed concentric layers of myo-
ﬁbroblasts around cancer cell nests. In most cases of frankly invasive 
adenocarcinoma, subepithelial myoﬁbroblasts were absent and bundles 
of myoﬁbroblasts emerged in cancer stroma. To further characterize the 
relationship to stromal invasion, we immmunostained adjacent sections 
for laminin-1 and collagen type 4 to highlight basement membranes, 
and then compared the results with smooth muscle α-actin staining. As 
expected, stromal invasion was associated with disruption of basement 
membranes and loss of a typical subepithelial pattern of myoﬁbroblasts. 
Interestingly, however, a subset of invasive adenocarcinomas partially 
retained subepithelial myoﬁbroblast, and survival analysis showed that 
invasive tumors with partial retention of subepithelial myoﬁbroblasts 
were associated with low rates of lymphatic and vascular invasion, 
lymph node involvement, and better patient survival. 
Conclusions: The results of this study suggest that subepithelial 
myoﬁbroblasts occur in bronchiolo-alveolar carcinomas, but they were 
gradually replaced by typical stromal myoﬁbroblasts during progres-
sion into invasive cancer. A subset of invasive adenocarcinomas retains 
subepithelial myoﬁbroblasts. Analysis of subepithelial myoﬁbroblasts 
may be helpful in deﬁning a subset of lung adenocarcinoma with good 
prognosis. 
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Background: Several researchers have reported the efﬁcacy of ad-
juvant chemotherapy in resected stage IB non-small cell lung cancer 
(NSCLC) patients. Due to the considerable variation in histological 
ﬁndings and outcomes of stage IB lung adenocarcinoma, it appeared 
there were unidentiﬁed subgroup factors. These factors affect treatment 
recommendations and choices. Identifying patients who do not need 
adjuvant chemotherapy saves patient stress and medical resources. This 
study’s aim was to investigate resected stage IB adenocarcinoma pa-
tient prognostic factors and identify a subgroup with a better outcome, 
where adjuvant chemotherapy might not be beneﬁcial and needed.
Methods: We reviewed records of 413 consecutive stage I lung 
adenocarcinoma patients who underwent complete surgical resection 
and systematic lymph node dissection at the National Cancer Center 
Hospital East from July 1992 through March 2000, to ﬁnd 106 stage IB 
patients for prognostic factor investigation. We evaluated four clinical 
factors: gender, age (<70 vs. ≥70 years), smoking history (positive vs. 
negative), and serum carcinoembryonic antigen (CEA) level (<5 vs. ≥5 
ng/ml). Seven pathological factors were also evaluated: maximum tu-
mor diameter (<5 vs. ≥5 cm), differentiation grade (well vs. moderately 
or poorly differentiated), lymphatic permeation (positive vs. negative), 
vascular invasion (positive vs. negative), pleural invasion (positive 
vs. negative), and bronchioloalveolar carcinoma (BAC) component 
dominance (positive vs. negative). BAC component dominance was 
considered positive if the histological evaluation found half or more of 
the tumor consisted of a BAC component. A subgroup with better out-
comes was identiﬁed and their survival compared with that of all stage 
IA patients who underwent surgical resection during the same period.
Results: The 5-year survival rate of all the stage IB lung adenocar-
cinoma patients was 81.7%. Univariate analyses found lymphatic 
permeation (p<0.001), vascular invasion (p=0.003), pleural invasion 
(p=0.001) and BAC-dominant histology (p=0.003) were signiﬁcant 
unfavorable prognostic factors. A multivariate analysis demonstrated 
positive pleural invasion (p=0.02) was an independent unfavorable 
prognostic factor. The stage IB lung adenocarcinoma patients 5-year 
survival rate with and without pleural invasion of 63% and 89%, 
respectively shows the invasion factor impact. Additionally, stage IB 
adenocarcinoma patients without pleural invasion overall survival rate 
was very similar to that of stage IA patients (92.7%; p=0.78). 
Conclusions: Pleural invasion is a factor that should be considered 
before recommending adjuvant chemotherapy to stage IB lung adeno-
carcinoma patients. The outcome for stage IB lung adenocarcinoma 
patients without pleural invasion is almost identical to stage IA patients 
where adjuvant chemotherapy has not shown an advantage. Adjuvant 
chemotherapy probably is not necessary or beneﬁcial for stage IB 
patients without pleural invasion.
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The presence of epidermal growth factor receptor (EGFR) tyrosine 
kinase (TK) mutations signiﬁcantly correlates with tumor sensitivity to 
tyrosine kinase inhibitor. Importantly, this mutation underlies respon-
siveness of the most predominant histologic subtype, adenocarcinoma. 
To clarify the correlation with EGFR mutations and pathological 
ﬁndings of adenocarcinomas of Japanese patients, detailed patho-
logical features of the tumor were examined. Total of 107 surgically 
resected adenocarcinomas were investigated. Seventeen cases treated 
with geﬁtinib for relapse were included. We reviewed medical records, 
pathology slides and examined EGFR mutations in exon 18-21. EGFR 
mutations were found in sixty ﬁve (60.7%) patients and detected in 
all four exons. EGFR mutations were signiﬁcantly associated with 
female gender (P<0.01), non-smoker status (P<0.05), hobnail cell type 
dominancy (P<0.0001), and papillary subtype (<0.0001). In addition, 
detailed pathological examination represented that the existence of 
bronchioloalveolar carcinoma (BAC) and micropapillary pattern (MPP) 
component was signiﬁcantly associated with EGFR mutations (P<0.05 
and <0.05, respectively). In seventeen patients with geﬁtinib treatment, 
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all cases but one with EGFR mutation exhibited a hobnail cell type 
dominancy. In the morphological features, hobnail cell type and the 
presence of BAC and MPP component are good predictors of EGFR 
mutations in pulmonary adenocarcinoma.
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Background: Pulmonary NE tumors are a distinct subset of tumors 
composing approximately 20% of all lung cancers. The main tumor 
types include typical carcinoid (TC), atypical carcinoid (AC), large cell 
NE carcinoma (LCNEC) and small cell carcinoma (SCLC). Although 
pulmonary NE tumors share certain morphologic, immunohistochemi-
cal, and ultrastructural features, they represent a broad clinicopatholog-
ic spectrum with varying morphologic features and biological behavior. 
Their clinicopathologic characteristics and relative grade of malignancy 
have not yet been well deﬁned and are still being assessed.
Methods: 317 cases of surgically resected pulmonary NE tumors 
diagnosed between 1992 and 2006 from the surgical pathology records 
of the Department of Pathology at Memorial Sloan-Kettering Cancer 
Center were reassessed retrospectively according to 2004 World Health 
Organization classiﬁcation. A detailed review of the gross and histo-
logic features was performed and the clinical features and followup 
were obtained from medical records. 
Results: Of 317 cases, there were 171 TC (53.9%), 19 AC (6.0%), 79 
LCNEC (24.9%) and 48 SCLC (15.2%). Patients were 133 men and 
184 women with an average age of 63 years. The median tumor size 
was 2.1 cm, ranging from 0.5 to 12.5 cm. LCNEC and SCLC cases 
tended to have larger tumor size (p<0.001) than TC and AC cases. 
Compared with other NE tumors, TC cases affected women signiﬁ-
cantly more often than men (p=0.01). Smoking was more frequent (%) 
and heavier (mean pack years) in LCNEC (98%, 61) and SCLC (97%, 
57) compared to TC (56%, 17) and AC (60%, 14) (p<0.001). The his-
tologic groups showed signiﬁcant correlations with several pathologic 
factors including vascular invasion (p<0.001), lymph node metastasis 
(p<0.001), pleural invasion (p<0.001), and stage (p<0.001). Mean age 
(yrs) for TC (56.7) and AC (58.7) patients was signiﬁcantly less than 
for SCLC (67.6) but not LCNEC (63.5) patients; LCNEC patients were 
signiﬁcantly younger than SCLC patients (p=0.008). 5-year survival 
rates for patients with all stages were 97.7% for TC, 78.9% for AC, 
51.9% for LCNEC and 37.5% for SCLC (p<0.001). Survival was 
signiﬁcantly better for TC compared to AC (p=0.002), better for AC 
compared to LCNEC (p=0.01) and SCLC (p=0.002) but there was no 
signiﬁcant difference in survival between LCNEC and SCLC (p=0.253) 
(Fig. 1). 
Conclusions: Our data conﬁrms that TC are low grade, AC intermedi-
ate grade and that LCNEC and SCLC are high grade NE lung tumors. 
We also found SCLC patients are signiﬁcantly older than LCNEC as 
well as both TC and AC patients. Smoking was more frequent and 
heavier in high grade NE tumor patients compared to both TC and 
AC patients. Further clinical and molecular studies may advance 
understanding of the optimal treatment and molecular biology of these 
tumors, especially in AC and LCNEC.
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Introduction: Primary rhabdoid tumor of lung is a rare histologi-
cal and clinical entity. Lung tumors with rhabdoid features have been 
included as a variant of large cell carcinoma in 1999 WHO classiﬁca-
tion of lung tumors. Primary lung rhabdoid is very rare with only 39 
cases reported till date and therefore clinical and radiological data are 
required to establish the diagnosis and exclude an asymptomatic renal 
primary We describe our experience with treating a case of rhabdoid 
tumor of lung with an aim to add to the existing body of literature about 
this rare histology.
Materials and Methods: A 36 year old lady presented to us in March 
2003 with a history of hemoptysis about 3-4 times. There was no histo-
ry of cough, expectoration, fever, chest pain or dyspnea. CT scan chest 
showed left lung upper lobe mass 5*5 cm abutting mediastinal vascular 
structures. Bronchial biopsy was strongly suspicious of malignancy 
Metastatic workup was normal. She underwent left pneumonectomy 
in May 2003. Post-op gross pathology report showed a 6*5 cm tumor. 
Microscopic examination revealed markedly cellular tumor, arranged 
in lobules and separated by ﬁbrocollagenous septae. Tumor cells were 
oval to polygonal in shape with abundant cytoplasm, vesicular nucleus, 
some of them having prominent nucleolus. Immunohistochemical stain-
ing showed positivity to S-100, Vimentin, and EMA. It was negative 
for LCA, HMB-45 and CEA. A diagnosis of undifferentiated carci-
noma, Rhabdoid Variant was made. Resected margins of bronchus and 
lymph nodes were free of tumor. She received adjuvant chemotherapy 
with inj. Paclitaxel(175mg/m2) i.v. D1, inj. Carboplatin AUC5 i.v. D2, 
4weekly for 6 cycles from august 2003 to January 2004. Follow up CT 
scan in November 2005 revealed liver metastases in segments 2 & 3 
with no disease in the chest. FNAC from the liver lesion showed metas-
